Fubotv earnings beat by $0.10, revenue topped estimates
Envoy Medical (TASE:BLWV), Inc., a company specializing in orthopedic, prosthetic, and surgical appliances and supplies, has announced that its Annual Meeting of Stockholders is scheduled for Wednesday, May 28, 2025. The company, currently trading at $1.26, has seen its stock decline by nearly 80% over the past year, with recent data from InvestingPro showing the price hovering near its 52-week low of $1.21. The meeting will take place at 3:00 p.m., Central time, at Fairfield Inn & Suites in Vadnais Heights, Minnesota.
Shareholders of record as of April 8, 2025, will be eligible to vote at the Annual Meeting. The company will provide further details on the agenda items for the meeting in its proxy statement, which will be filed with the Securities and Exchange Commission.
The company has also set a deadline for April 20, 2025, for the receipt of any shareholder proposals or director nominations to be presented at the Annual Meeting. This deadline is in accordance with the company's Amended and Restated Bylaws and Rule 14a-8 under the Securities Exchange Act of 1934. Proposals and nominations must be submitted in writing to the corporate secretary and meet the informational content requirements outlined in the Bylaws.
Notably, Envoy Medical has adjusted the timing of its annual meeting from October to May, necessitating the announcement of this new deadline for proposals and nominations. Compliance with Delaware law, the company's Bylaws, and SEC regulations is required for all submissions.
The company, formerly known as Anzu Special Acquisition Corp I, underwent a name change on January 15, 2021. Envoy Medical's common stock and warrants are listed on The Nasdaq Stock Market LLC under the symbols COCH and COCHW, respectively.
This announcement is based on a press release statement and aims to inform shareholders and the public of the upcoming Annual Meeting and related deadlines for shareholder participation. Envoy Medical's Chief Financial Officer, David R. Wells, signed off on the report dated April 10, 2025.
In other recent news, Envoy Medical has faced a significant challenge as it received a notification from The Nasdaq Stock Market for non-compliance with a critical listing rule. The company has failed to maintain a minimum market value of $35 million for its listed securities over 31 consecutive business days. To avoid delisting, Envoy Medical must meet the market value requirement for at least ten consecutive business days before August 25, 2025. In a positive development, Envoy Medical announced the expansion of its patent portfolio with new patents issued in the United States, Japan, and Hong Kong. The U.S. patents cover an implantable cochlear system with innovative features, while the Japanese patents address cochlear implant systems with a common power supply. The Hong Kong patent focuses on the programming of cochlear implant accessories. These patents reflect Envoy Medical's ongoing efforts to innovate in the hearing health sector. Investors will be closely monitoring how these developments impact the company's market value and compliance status with Nasdaq.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.